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designed to support both the collection of PRO data and the
development of an economic model.
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OBJECTIVES: Behavioral health interventions traditionally use
a simple dichotomous outcome criterion: ‘success’ or ‘failure’.
In reality, though, behavior change is a complex process in
which several steps towards success are taken. There has been
little consideration, however, about whether future behavior
change should be incorporated in cost-effectiveness analyses
(CEAs). The aim of the present review is to identify and evalu-
ate the usage of cognitive, intermediate outcomes in CEAs of
behavioral interventions. METHODS: Electronic data sources
(PsycInfo, WebofScience, Medline, ScienceDirect and Scopus)
were searched for CEAs published before February 2008.
RESULTS: Most CEAs and CUAs reporting cognitive, interme-
diate outcomes of behavior change fail to incorporate partial
behavior changes. Only nine studies were eligible for inclusion
in this review. Smith et al 2007 [1] conducted the only study in
which partial behavior change was incorporated in the ﬁnal
outcome by modeling cognitive, intermediate outcomes: the
stages of change, derived from the Transtheoretical model
(TTM). The TTM is a stage-oriented model that describes the
process by which a change in behavior takes place. It describes
the readiness to change and the processes employed by indi-
viduals to achieve behavioral change. With inclusion of future
behavior change, Smith et al showed that the incremental cost-
effectiveness ratio declined compared to the standard analysis.
CONCLUSIONS: The results suggest that CEAs of behavioral
interventions can be further optimized by the measurement of
intermediate outcomes and use these to determine partial
behavior change at the end of an intervention period as well. In
other words, when partial behavior change and relapse rates
are incorporated in CEAs of behavioral treatments, a more
realistic and transparent ﬁnal outcome can be calculated. [1]
Smith, MY, Cromwell, J, DePue, J, et al. Determining the cost-
effectiveness of a computer-based smoking cessation interven-
tion in primary care. Managed Care 2007;16:48–55.
PMC20
QUANTITATIVE APPROACHTO DETERMINETHE EFFECT OF
SEGMENTATION ON REVENUE GENERATION, POSITIONING
AND PRICING OF PHARMACEUTICALS
Bolle M1, Mukku SR2, Sparrowhawk K2,Tutt S2
1University of Cambridge, Cambridge, UK, 2PriceSpective, London, UK
OBJECTIVES: To develop a quantitative model that can deter-
mine the effect of segmentation and positioning on revenue
generation based on different variables, health economic consid-
erations and pricing scenarios, creating a tool which is easy to use
for the ﬁrst evaluation of options. METHODS: Literature review
and interviews with industry experts were conducted followed by
the development of qualitative framework, logic and the subse-
quently a quantitative model. The model was tested and vali-
dated using real life examples. RESULTS: A qualitative model
was developed which presents an iterative strategy to align stake-
holders’ interest with different scenarios of segmentation. From a
given asset base of active ingredients, the pharmaceutical
company deﬁnes therapeutic areas for a component and deter-
mines segments within them, evaluating both attractiveness and
speciﬁc propositions for patients, payers and prescribers in com-
prehensive scenarios. For the payer’s perspective in particular,
health economic beneﬁts of the proposed segmentation approach
must be contemplated. Following this analysis, objectives and
strategies for the chosen segments are developed and a holistic
value proposition can be delivered to the market. Ideally, the
process should be initiated early during development in order to
design clinical trials according to the segmentation strategy. The
process should also be monitored throughout the marketing and
sales process in order to make improvements, and to react to
changes in health care policies or the competitive landscape.
Following the qualitative analysis, a quantitative model was
developed in Excel that captures the effect of multiple variables
such as age, gender, disease severity, co-morbidities, insurance
type and multiple price points on revenue generation, positioning
and pricing of pharmaceuticals. The model was tested and vali-
dated using the example of bipolar disorder (BPD) in women
with childbearing potential. A new product with lower teratoge-
nic risks was evaluated along different segmentation scenarios in
order to determine improved overall cost-effectiveness when
compared to conventional treatments. CONCLUSIONS: Seg-
mentation is an important tool that could lead to better revenue
generation from the company’s perspective and is accepted posi-
tively by payers due to optimized budget impact with better
health outcomes.
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BACKGROUND: In model-based health economic evaluations,
to achieve a given level of precision surrounding modelled
outputs there is a trade-off between treatment effect estimates
and the computational time associated with the programming
format used to ‘code’ the model. OBJECTIVES: To explore the
relationship between modelled effect size, statistical precision
and the computational time associated with two commonly used
programming frameworks. METHODS: A published and vali-
dated cost-utility discrete event simulation (DES) diabetes model
(Cardiff model) was programmed in MS Excel with Visual Basic
(VB), and more recently reprogrammed in C as with other
models in this area, to illustrate the efﬁciency gains in terms of
computational speed achieved under different programming
frameworks. A treatment effect of 0.4% HbA1c improvement
was applied to a mean cohort proﬁle of 10,000 patients; preci-
sion in the predicted number of clinical events was used to assess
relative efﬁciency of VB and C. RESULTS: In the C programmed
model in order to show a signiﬁcant difference at the 95% level
in the predicted number of events in the control and treatment
arms required 50 iterations of the model using mean values. This
equated to a model run time of 1 minute. The equivalent number
of iterations in VB took 133 minutes to demonstrate a signiﬁcant
difference in the predicted number of events. Typically, one-way
sensitivity analysis using this model to explore 40 scenarios
would equate to a run time of 40 minutes in C and 5,320 minutes
(88.7 hours) in VB. CONCLUSIONS: Programming format can
impact the computational time associated with running the
model with subsequent practical implications for the usability of
the model. We conclude that with reasonably complex models,
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